Bruce Shiramizu to Child
This is a "connection" page, showing publications Bruce Shiramizu has written about Child.
Connection Strength
0.601
-
Shiramizu B, Mussolin L, Woessmann W, Klapper W. Paediatric non-Hodgkin lymphoma - perspectives in translational biology. Br J Haematol. 2016 05; 173(4):617-24.
Score: 0.077
-
Shiramizu B, Goldman S, Smith L, Agsalda-Garcia M, Galardy P, Perkins SL, Frazer JK, Sanger W, Anderson JR, Gross TG, Weinstein H, Harrison L, Barth MJ, Mussolin L, Cairo MS. Impact of persistent minimal residual disease post-consolidation therapy in children and adolescents with advanced Burkitt leukaemia: a Children's Oncology Group Pilot Study Report. Br J Haematol. 2015 Aug; 170(3):367-71.
Score: 0.072
-
Shiramizu B, Goldman S, Kusao I, Agsalda M, Lynch J, Smith L, Harrison L, Morris E, Gross TG, Sanger W, Perkins S, Cairo MS. Minimal disease assessment in the treatment of children and adolescents with intermediate-risk (Stage III/IV) B-cell non-Hodgkin lymphoma: a children's oncology group report. Br J Haematol. 2011 Jun; 153(6):758-63.
Score: 0.054
-
Shiramizu B, Hu N, Frisque RJ, Nerurkar VR. High prevalence of human polyomavirus JC VP1 gene sequences in pediatric malignancies. Cell Mol Biol (Noisy-le-grand). 2007 May 15; 53(3):4-12.
Score: 0.041
-
Shiramizu B, Lau E, Tamamoto A, Uniatowski J, Troelstrup D. Feasibility assessment of cerebrospinal fluid from HIV-1-infected children for HIV proviral DNA and monocyte chemoattractant protein 1 alleles. J Investig Med. 2006 Dec; 54(8):468-72.
Score: 0.040
-
Shiramizu B, Perkins SL, Bergeron S, Lones M, Kelly K, Weiner M, Cairo MS. Assessing immunoglobulin heavy chain rearrangements in pediatric CD20-positive and CD20-negative classic Hodgkin's disease. Clin Lymphoma. 2004 Dec; 5(3):184-9.
Score: 0.035
-
Shiramizu B, Mick P. Epigenetic changes in the DAP-kinase CpG island in pediatric lymphoma. Med Pediatr Oncol. 2003 Dec; 41(6):527-31.
Score: 0.033
-
Sabesan V, Cairo MS, Lones MA, Perkins SL, Morris E, Sposto R, Van De Ven C, Shiramizu B. Assessment of minimal residual disease in childhood non-hodgkin lymphoma by polymerase chain reaction using patient-specific primers. J Pediatr Hematol Oncol. 2003 Feb; 25(2):109-13.
Score: 0.031
-
Shiramizu B, Yu Q, Hu N, Yanagihara R, Nerurkar VR. Investigation of TT virus in the etiology of pediatric acute lymphoblastic leukemia. Pediatr Hematol Oncol. 2002 Dec; 19(8):543-51.
Score: 0.030
-
Cabalo E, Wilkinson R, Lu NT, Shimizu S, Melish M, McClain KL, Jenson HB, Shiramizu B. Molecular analysis and pathology of a second pediatric HIV-associated Burkitt lymphoma. Pediatr Pathol Mol Med. 2002 Nov-Dec; 21(6):525-30.
Score: 0.030
-
Shiramizu B, Chang CW, Cairo MS. Absence of human herpesvirus-6 genome by polymerase chain reaction in children with Hodgkin disease: a Children's Cancer Group Lymphoma Biology Study. J Pediatr Hematol Oncol. 2001 Jun-Jul; 23(5):282-5.
Score: 0.027
-
Goldman S, Barth M, Shiramizu B, Shi Q, Hochberg J, Klejmont L, Harrison L, Basso J, Chu Y, Islam H, Gerard P, Agsalda-Garcia M, Shieh T, Oesterheld J, Heym K, Kirov I, Drachtman R, Harker-Murray P, Perkins S, Miles RR, Cairo M. A dose substitution of anthracycline intensity with dose-dense rituximab in children and adolescents with good-risk mature B-cell lymphoma. Leukemia. 2021 10; 35(10):2994-2997.
Score: 0.027
-
Frazer JK, Li KJ, Galardy PJ, Perkins SL, Auperin A, Anderson JR, Pinkerton R, Buxton A, Gross TG, Michon J, Leverger G, Weinstein HJ, Harrison L, Shiramizu B, Barth MJ, Goldman SC, Patte C, Cairo MS. Excellent outcomes in children and adolescents with CNS+ Burkitt lymphoma or other mature B-NHL using only intrathecal and systemic chemoimmunotherapy: results from FAB/LMB96 and COG ANHL01P1. Br J Haematol. 2019 04; 185(2):374-377.
Score: 0.023
-
Goldman S, Smith L, Galardy P, Perkins SL, Frazer JK, Sanger W, Anderson JR, Gross TG, Weinstein H, Harrison L, Shiramizu B, Barth M, Cairo MS. Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report. Br J Haematol. 2014 Nov; 167(3):394-401.
Score: 0.017
-
Grossman M, Shiramizu B. Evaluation of lymphadenopathy in children. Curr Opin Pediatr. 1994 Feb; 6(1):68-76.
Score: 0.017
-
Goldman S, Smith L, Anderson JR, Perkins S, Harrison L, Geyer MB, Gross TG, Weinstein H, Bergeron S, Shiramizu B, Sanger W, Barth M, Zhi J, Cairo MS. Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children's Oncology Group report. Leukemia. 2013 Apr; 27(5):1174-7.
Score: 0.015
-
Magrath IT, Shiramizu B. Biology and treatment of small non-cleaved cell lymphoma. Oncology (Williston Park). 1989 Nov; 3(11):41-53; discussion 53-4, 56, 59-60.
Score: 0.012
-
Griffin TC, Weitzman S, Weinstein H, Chang M, Cairo M, Hutchison R, Shiramizu B, Wiley J, Woods D, Barnich M, Gross TG. A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2009 Feb; 52(2):177-81.
Score: 0.012
-
Yu Q, Shiramizu B, Nerurkar VR, Hu N, Shikuma CM, Melish ME, Cascio K, Imrie A, Lu Y, Yanagihara R. TT virus: preferential distribution in CD19(+) peripheral blood mononuclear cells and lack of viral integration. J Med Virol. 2002 Feb; 66(2):276-84.
Score: 0.007